St. Paul MN – Some of the things seven-year-old Holli loves about school are getting candy on her birthday, math (she could do math all day!), and playing on the swings during recess. Her specialized paraprofessional, Mr. Tyler, joins her in swinging and in hallway banter as they navigate Holli’s...
Latest News
Bedford, Mass. — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments. “We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome,...
Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced that Albert Seymour, Ph.D., President and Chief Executive Officer, will participate in the “Gene Editing Corporate Panel” during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET.
Melbourne, Australia – Researchers, led by University of Melbourne’s Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), discovered distinct mechanisms controlling different types of immune cells, and found that, by precisely targeting these mechanisms, they could selectively...
SHANGHAI, China — Hope Medicine Inc. , a clinical-stage innovative biopharmaceutical company, announced recently that the company has completed a Phase Ib study, “An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period”. This study is...
DEERFIELD, Ill. – Horizon Therapeutics (Nasdaq: HZNP) and the Cubs announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, which will include an innovative, citywide science camp and fair that allows Chicagoland-area middle and high school students to explore the connection between science and baseball as...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum clinical trial, indicating UPLIZNA may provide durable efficacy and a favorable safety profile for African Americans with NMOSD. These data were presented during the 15th World Congress on Controversies in Neurology (CONy Virtual), Sept....
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus (SLE)....
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) announced that it has reached an agreement to purchase a drug product manufacturing facility from EirGen Pharma, an OPKO Health Company (Nasdaq: OPK) in Waterford, Ireland. The facility, which is located in an IDA Ireland business park, includes a filling line and lyophiliser,...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela acquisition provides multiple opportunities to drive long-term growth and solidify our future as an innovation-driven biotech company,” said Tim Walbert, chairman, president and chief executive officer, Horizon....